Safety and efficacy of statins – Authors' reply

The Lancet

Volumn 389, Issue 10074, 2017, Pages 1099-1100

  Collins, Rory ^a   Armitage, Jane ^a   Baigent, Colin ^a   Smith, George Davey ^b   Smeeth, Liam ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADVERSE OUTCOME; AEROBIC EXERCISE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HUMAN; LETTER; MUSCLE EXERCISE; MUSCLE STRENGTH; MYALGIA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 85015679003     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30717-1     Document Type: Letter

References (12)

1. 1 Smith, SC Jr, Grundy, SM, Reply: statin dose based on limited evidence. J Am Coll Cardiol 65 (2015), 759–760.
2. 2 Abramson, JD, Rosenberg, HG, Jewell, N, Wright, JM, Should people at low risk of cardiovascular disease take a statin?. BMJ, 347, 2013, f6123.
3. 3 Godlee, F, Adverse effects of statins. BMJ, 348, 2014, g3306.
4. 4 Collins, R, Reith, C, Emberson, J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
5. 5 Parker, BA, Capizzi, JA, Grimaldi, AS, et al. Effect of statins on skeletal muscle function. Circulation 127 (2013), 96–103.
6. 6 Wasserstein, RL, Lazar, NA, The ASA's statement on p-values: context, process, and purpose. Am Stat 70 (2016), 129–133.
7. 7 Kjekshus, J, Apetrei, E, Barrios, V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007), 2248–2261.
8. 8 Ganga, HV, Slim, HB, Thompson, PD, A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168 (2014), 6–15.
9. 9 Keech, A, Collins, R, MacMahon, S, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 15 (1994), 255–269.
10. 10 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
11. 11 Postmus, I, Deelen, J, Sedaghat, S, et al. LDL cholesterol still a problem in old age? A Mendelian randomization study. Int J Epidemiol 44 (2015), 604–612.
12. 12 Greenland, P, Bonow, RO, Interpetation and use of another statin guideline. JAMA 316 (2016), 1977–1978.